Literature DB >> 16671478

Histamine receptors influence blood-spinal cord barrier permeability, edema formation, and spinal cord blood flow following trauma to the rat spinal cord.

H S Sharma1, P Vannemreddy, R Patnaik, S Patnaik, S Mohanty.   

Abstract

The role of histamine in edema formation, blood-spinal cord barrier (BSCB) permeability, and spinal cord blood flow (SCBF) following spinal cord injury (SCI) was examined using modulation of histamine H1, H2, and H3 receptors in the rat. Focal trauma to the spinal cord at the T10-11 level significantly increased spinal cord edema formation, BSCB permeability to protein tracers and SCBF reduction in the T9 and T12 segments. Pretreatment with histamine H1 receptor antagonist mepyramine (1 mg, 5 mg, and 10 mg/kg, i.p.) did not attenuate spinal pathophysiology following SCI. Blockade of histamine H2 receptors with cimetidine or ranitidine (1 mg, 5 mg, or 10 mg/kg 30 minutes before injury) significantly reduced early pathophysiological events in a dose dependent manner. The effects of ranitidine were far superior to cimetidine in identical doses. Pretreatment with a histamine H3 receptor agonist alpha-methylhistamine (1 mg and 2 mg/kg/i.p.), that inhibits histamine synthesis and release in the CNS, thwarted edema formation, BSCB breakdown, and SCBF disturbances after SCI. The lowest dose of histamine H3 agonist was most effective. Blockade of histamine H3 receptors with thioperamide (1 mg, 5 mg/kg, i.p.) exacerbated spinal cord pathology. These observations suggest that stimulation of histamine H3 receptors and blockade of histamine H2 receptors is neuroprotective in SCI.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16671478     DOI: 10.1007/3-211-30714-1_67

Source DB:  PubMed          Journal:  Acta Neurochir Suppl        ISSN: 0065-1419


  6 in total

Review 1.  Early microvascular reactions and blood-spinal cord barrier disruption are instrumental in pathophysiology of spinal cord injury and repair: novel therapeutic strategies including nanowired drug delivery to enhance neuroprotection.

Authors:  Hari Shanker Sharma
Journal:  J Neural Transm (Vienna)       Date:  2010-12-16       Impact factor: 3.575

2.  Histamine H3 Inverse Agonist BF 2649 or Antagonist with Partial H4 Agonist Activity Clobenpropit Reduces Amyloid Beta Peptide-Induced Brain Pathology in Alzheimer's Disease.

Authors:  Ranjana Patnaik; Aruna Sharma; Stephen D Skaper; Dafin F Muresanu; José Vicente Lafuente; Rudy J Castellani; Ala Nozari; Hari S Sharma
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

3.  Safe range of shortening the middle thoracic spine, an experimental study in canine.

Authors:  Le Ji; Xiaoying Ma; Wenchen Ji; Shengli Huang; Min Feng; Jingyuan Li; Lisong Heng; Yajuan Huang; Binshang Lan
Journal:  Eur Spine J       Date:  2020-01-01       Impact factor: 3.134

4.  Central histamine H3 receptor signaling negatively regulates susceptibility to autoimmune inflammatory disease of the CNS.

Authors:  Cory Teuscher; Meena Subramanian; Rajkumar Noubade; Jian Feng Gao; Halina Offner; James F Zachary; Elizabeth P Blankenhorn
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-04       Impact factor: 11.205

Review 5.  Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015-2020.

Authors:  Niklas Huntemann; Leoni Rolfes; Marc Pawlitzki; Tobias Ruck; Steffen Pfeuffer; Heinz Wiendl; Sven G Meuth
Journal:  Drugs       Date:  2021-06-04       Impact factor: 9.546

6.  Histamine receptor agonist alleviates severe cardiorenal damages by eliciting anti-inflammatory programming.

Authors:  Kazuyuki Noguchi; Junji Ishida; Jun-Dal Kim; Naoto Muromachi; Koichiro Kako; Hayase Mizukami; Weizhe Lu; Tomohiro Ishimaru; Shohei Kawasaki; Shuzo Kaneko; Joichi Usui; Hiroshi Ohtsu; Kunihiro Yamagata; Akiyoshi Fukamizu
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-28       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.